Immune Thrombotic Thrombocytopenic Purpura: A Review., PMID:40388146
[Enriching plasma exosomes for proteomic analysis using a phosphatidylserine-imprinted polymer]., PMID:40331617
Caplacizumab use in immune-mediated thrombotic thrombocytopenic purpura: an international multicentre retrospective Cohort study (The Capla 1000+ project)., PMID:40235949
Optimization of nanobody caplacizumab via computational design., PMID:40226960
Early administration of caplacizumab combined with plasma exchange for thrombotic microangiopathy due to malignant hypertension: a case report., PMID:40029564
[100 years thrombotic thrombocytopenic purpura (TTP) - lessons learned?]., PMID:39504978
Refining the standard of care in immune thrombotic thrombocytopenic purpura., PMID:39356816
Caplacizumab as an add-on therapy in a 7-year-old girl with exacerbated immune-mediated thrombotic thrombocytopenic purpura, a case report and literature review., PMID:39233868
Immune Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, Therapy and Open Issues., PMID:38984099
Caplacizumab in pediatric immune thrombotic thrombocytopenic purpura: the UK TTP Registry experience., PMID:38968147
[Advances in the treatment of thrombotic thrombocytopenic purpura]., PMID:38960658
Novel mechanisms of action of emerging therapies of hereditary thrombotic thrombocytopenic purpura., PMID:38752747
Nanobody activator improves sensitivity of the von Willebrand factor activity assay to multimer size., PMID:38704122
Targeting neutrophil extracellular trap accumulation under flow in patients with immune-mediated thrombotic thrombocytopenic purpura., PMID:38513079
Conformational activation and inhibition of von Willebrand factor by targeting its autoinhibitory module., PMID:38290109
Successful management of refractory immune-mediated thrombotic thrombocytopenic purpura during pregnancy and delivery using the anti-VWF nanobody caplacizumab., PMID:38168722
True vs. false immune-mediated thrombotic thrombocytopenic purpura exacerbations: a clinical case in the caplacizumab era., PMID:37994623
Mirror-Image Single-Domain Antibody for a Novel Nonimmunogenic Drug Scaffold., PMID:37883660
Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023., PMID:37689812
Quantitative super-resolution imaging of platelet degranulation reveals differential release of von Willebrand factor and von Willebrand factor propeptide from alpha-granules., PMID:37061132
Frontiers in pathophysiology and management of thrombotic thrombocytopenic purpura., PMID:36757521
A nanobody against the VWF A3 domain detects ADAMTS13-induced proteolysis in congenital and acquired VWD., PMID:36564031
Full-length recombinant antibodies from Escherichia coli: production, characterization, effector function (Fc) engineering, and clinical evaluation., PMID:36018829
[Development of a novel aptamer blocking the interaction between the VWF A1 domain and platelet GP Ib for the treatment of arterial thrombosis]., PMID:35662162
Von Willebrand factor assays in patients with acquired immune thrombotic thrombocytopenia purpura treated with caplacizumab., PMID:35262910
Advances in the management of TTP., PMID:35216839
Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura., PMID:35000278
Osteoprotegerin modulates platelet adhesion to von Willebrand factor during release from endothelial cells., PMID:34816579
Caplacizumab Model-Based Dosing Recommendations in Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura., PMID:34699078
First use of the anti-VWF nanobody caplacizumab to treat iTTP in pregnancy., PMID:34585743
COVID-19 as a Potential Trigger for Immune Thrombotic Thrombocytopenic Purpura and Reason for an Unusual Treatment: A Case Report., PMID:34327693
High-resolution structure of the vWF A1 domain in complex with caplacizumab, the first nanobody-based medicine for treating acquired TTP., PMID:34144500
Activation of von Willebrand factor via mechanical unfolding of its discontinuous autoinhibitory module., PMID:33883551
Redefining outcomes in immune TTP: an international working group consensus report., PMID:33529333
Emerging mechanisms to modulate VWF release from endothelial cells., PMID:33301925
Successful use of caplacizumab in a case of refractory acquired thrombotic thrombocytopenic purpura following subacute thyroiditis., PMID:33223471
Successful management of three patients with autoimmune thrombotic thrombocytopenic purpura with paradigm-changing therapy: Caplacizumab, steroids, plasma exchange, rituximab, and intravenous immunoglobulins (CASPERI)., PMID:33221124
Novel aptamer to von Willebrand factor A1 domain (TAGX-0004) shows total inhibition of thrombus formation superior to ARC1779 and comparable to caplacizumab., PMID:33131252
Assessment and Monitoring of Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): Strategies to Improve Outcomes., PMID:33061729
von Willebrand Factor Is a Critical Mediator of Deep Vein Thrombosis in a Mouse Model of Diet-Induced Obesity., PMID:32967458
A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura., PMID:32876503
New Therapeutic Targets and Treatment Options for Thrombotic Microangiopathy: Caplacizumab and Ravulizumab., PMID:32715723
ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP., PMID:32634237
Novel antiplatelet strategies targeting VWF and GPIb., PMID:32614622
Caplacizumab for treatment of thrombotic thrombocytopenic purpura in a patient with anaphylaxis to fresh-frozen plasma., PMID:32358818
The von Willebrand Factor A1 domain mediates thromboinflammation, aggravating ischemic stroke outcome in mice., PMID:32107335
Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura., PMID:32095224
Taking Empiricism out of Immune Thrombotic Thrombocytopenic Purpura: Current and Future Treatment Strategies., PMID:31645275
Quantification of coagulation factor VIII in human plasma with liquid chromatography tandem mass spectrometry using a selective sample purification with camelid nanobodies., PMID:31398627
For research use only. Not for human or drug use.
